NASDAQ:AARD Aardvark Therapeutics (AARD) Stock Price, News & Analysis $12.86 +1.53 (+13.50%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Aardvark Therapeutics Stock (NASDAQ:AARD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aardvark Therapeutics alerts:Sign Up Key Stats Today's Range$11.10▼$13.5650-Day Range$7.00▼$13.4052-Week Range$4.88▼$19.58Volume161,986 shsAverage Volume129,178 shsMarket Capitalization$279.01 millionP/E RatioN/ADividend YieldN/APrice Target$31.50Consensus RatingBuy Company OverviewAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Read More… Receive AARD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AARD Stock News HeadlinesAardvark Therapeutics (NASDAQ:AARD) Trading 7.6% Higher - Time to Buy?April 23, 2025 | americanbankingnews.comAardvark Therapeutics, Inc. Common Stock (AARD)April 18, 2025 | finance.yahoo.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.May 2, 2025 | Paradigm Press (Ad)AARD Aardvark Therapeutics, Inc.April 2, 2025 | seekingalpha.comRBC Capital Sticks to Their Buy Rating for Aardvark Therapeutics, Inc. (AARD)April 2, 2025 | markets.businessinsider.comAardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business HighlightsMarch 31, 2025 | globenewswire.comDrugmaker Soleno Soars on Approval to Treat Never Ending HungerMarch 27, 2025 | finance.yahoo.comAardvark Therapeutics price target raised to $26 from $22 at BofAMarch 27, 2025 | markets.businessinsider.comSee More Headlines AARD Stock Analysis - Frequently Asked Questions How have AARD shares performed this year? Aardvark Therapeutics' stock was trading at $13.30 at the start of the year. Since then, AARD stock has decreased by 3.3% and is now trading at $12.86. View the best growth stocks for 2025 here. When did Aardvark Therapeutics IPO? Aardvark Therapeutics (AARD) raised $100 million in an initial public offering on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets acted as the underwriters for the IPO. When did Aardvark Therapeutics' quiet period expire? Aardvark Therapeutics' quiet period expired on Tuesday, March 25th. Aardvark Therapeutics had issued 5,888,000 shares in its public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. During Aardvark Therapeutics' quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Aardvark Therapeutics? Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AARD Previous SymbolNASDAQ:AARD CIK1774857 WebN/A Phone(858) 225-7696FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$31.50 High Stock Price Target$50.00 Low Stock Price Target$21.00 Potential Upside/Downside+158.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares21,696,000Free FloatN/AMarket Cap$264.26 million OptionableN/A BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:AARD) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.